Credibility of Mike and Paul?

Quote

Anonymous

Guest
Seems like the street didn't necessarily go for the "top line grew 26% in Q4," "saving $$ with no lung trial" and "we reduced expenses through EE reductions" tactic to move the stock higher at the biotech conference. Stock didn't not budge and even went down on the news. Why didn't they keep the good news for the analyst call?????

My friend and the entire sales team was told by Paul and Mike on a national conf call 1 month ago she was fine with his/her position ("commercial size is right".......Mike Schick) and now he/she's gone. I love selling this drug but Schick / Paul are whoring out their credibility at the expense of motivating and leading their employees as they should. I bet Paul couldn't name the top 5 cancer programs in the US prior to Schick helping him understand the business in Q4 as he lives in Wisconsin and barely commutes to Denver or NJ.

I used to like Mike and Tim but they are different now.

Seattle Genetics will be a fun company to work for when they hire the sales team. Folotyn will be stuck to getting salvage business once brentuximab is FDA approved with 75%+ response rates. MDs will quickly go off label using that drug in more than ALCL and Hodgkins from what my KOLs are telling me.
 




Anonymous said:
Seattle Genetics will be a fun company to work for when they hire the sales team. Folotyn will be stuck to getting salvage business once brentuximab is FDA approved with 75%+ response rates. MDs will quickly go off label using that drug in more than ALCL and Hodgkins from what my KOLs are telling me.
Click to expand...

Your KOLs obviously don't know that much. SGEN's drug is a targeted therapy that works on only CD30 positive patients. To use off label on non CD30 positive patients doesn't work at all, and most importantly won't get reimbursed.
 




You will hear "the sales force is the same size", "people were promoted", "you have more resources" blah, blah, blah. 13% reduction in employees, and there WERE layoffs in the field.

There is no room for trust in this organization any more....run as fast as you can!
 




on the SGEN / CD30 reply..........

I believe my KOLs more than my biased lying company.

SGEN started with Hodgkins and ALCL because those types of lymphoma express CD30 more than others. Ask your MDs about the CTCL subtypes and how prevelant CD30 positive is (quite a bit). Also, there are more PTCL subtypes than ALCL that express CD30 the study just did not look at those because ALCL express CD30 more than any other subtype.


Wouldn't you try a 80% response drug chance versus a 27% (+/-) response if you had the disease??? I sure would. You can always use Folotyn if other drugs dont work first which is where we are heading.
 




Anonymous said:
on the SGEN / CD30 reply..........

I believe my KOLs more than my biased lying company.

SGEN started with Hodgkins and ALCL because those types of lymphoma express CD30 more than others. Ask your MDs about the CTCL subtypes and how prevelant CD30 positive is (quite a bit). Also, there are more PTCL subtypes than ALCL that express CD30 the study just did not look at those because ALCL express CD30 more than any other subtype.


Wouldn't you try a 80% response drug chance versus a 27% (+/-) response if you had the disease??? I sure would. You can always use Folotyn if other drugs dont work first which is where we are heading.
Click to expand...

Spot on. And the band plays on.
 




Anonymous said:
Ask your MDs about the PTCL subtypes and watch their eyes glaze over in fall into a deep deep sleep. Awake your customer and ask him why you havent used folotyn yet? and the reply will be....


I havent seen a PTCL patient since.....(fill in the blank). Credibility? Not found with Mike or Paul--which is the fuse has been lit. There is no credible leadership only yes men.
Click to expand...
 
















Paul has zero credibility with the sales or marketing team. The exception was Caruso who he worked with at BMS. No one respects him internally whether its clinical or commercial. A little angry napolean.

Paul does have credibility with the board of directors who hired him. So Paul stays.

His ability to lead and manage the business to the point it is today is his annual performance appraisal. The stock is down 50% since approval, he forcasted 75 Million in sales for 2010, he got 30 million, fired his only friend in the company to save his own ass. Yet, he will receive several hundred thousands $ in bonus for these accomplishments.

Mike works for Paul. What is he supposed to do? Schick knows that PTCL will not keep the lights on nor will our 6 marketing points. Schick knows that mom and pop hems will never treat rrPTCL as does Paul. Owen Oconnor made this crystal clear a long time ago, market research as well as CRM data has only reaffirmed this. But this is ignored.

rrPTCl was meant to be a starting point to sell the company to a big pharma player needing an entry into oncology or as a complimentary product to its portfolio...someone like BMS.....it didnt happen and here we are
 




Anonymous said:
Paul has zero credibility with the sales or marketing team. The exception was Caruso who he worked with at BMS. No one respects him internally whether its clinical or commercial. A little angry napolean.

Paul does have credibility with the board of directors who hired him. So Paul stays.

His ability to lead and manage the business to the point it is today is his annual performance appraisal. The stock is down 50% since approval, he forcasted 75 Million in sales for 2010, he got 30 million, fired his only friend in the company to save his own ass. Yet, he will receive several hundred thousands $ in bonus for these accomplishments.

Mike works for Paul. What is he supposed to do? Schick knows that PTCL will not keep the lights on nor will our 6 marketing points. Schick knows that mom and pop hems will never treat rrPTCL as does Paul. Owen Oconnor made this crystal clear a long time ago, market research as well as CRM data has only reaffirmed this. But this is ignored.

rrPTCl was meant to be a starting point to sell the company to a big pharma player needing an entry into oncology or as a complimentary product to its portfolio...someone like BMS.....it didnt happen and here we are
Click to expand...

This.
 




Anonymous said:
Paul has zero credibility with the sales or marketing team. The exception was Caruso who he worked with at BMS. No one respects him internally whether its clinical or commercial. A little angry napolean.

Paul does have credibility with the board of directors who hired him. So Paul stays.

His ability to lead and manage the business to the point it is today is his annual performance appraisal. The stock is down 50% since approval, he forcasted 75 Million in sales for 2010, he got 30 million, fired his only friend in the company to save his own ass. Yet, he will receive several hundred thousands $ in bonus for these accomplishments.

Mike works for Paul. What is he supposed to do? Schick knows that PTCL will not keep the lights on nor will our 6 marketing points. Schick knows that mom and pop hems will never treat rrPTCL as does Paul. Owen Oconnor made this crystal clear a long time ago, market research as well as CRM data has only reaffirmed this. But this is ignored.

rrPTCl was meant to be a starting point to sell the company to a big pharma player needing an entry into oncology or as a complimentary product to its portfolio...someone like BMS.....it didnt happen and here we are
Click to expand...

Someones head in home office should roll for posting this. It is 100% truth something leadership does not want to hear or see.
 
















Top Bottom
Back
Quote